| Title: | A genome-first approach to variants in MLXIPL and their association with hepatic steatosis and plasma lipids. |
| Journal: | Hepatology Communications |
| Published: | 26 Apr 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38668731/ |
| DOI: | https://doi.org/10.1097/hc9.0000000000000427 |
| URL: | http://dx.doi.org/10.1097/hc9.0000000000000427 |
| Citations: | 1 (1 in last 2 years) as of 8 Aug 2024 |
Publication 9798
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: Common variants of the max-like protein X (MLX)-interacting protein-like (MLXIPL) gene, encoding the transcription factor carbohydrate-responsive element-binding protein, have been shown to be associated with plasma triglyceride levels. However, the role of these variants in steatotic liver disease (SLD) is unclear.</p>
METHODS: We used a genome-first approach to analyze a variety of metabolic phenotypes and clinical outcomes associated with a common missense variant in MLXIPL, Gln241His, in 2 large biobanks: the UK Biobank and the Penn Medicine Biobank.</p>
RESULTS: Carriers of MLXIPL Gln241His were associated with significantly lower serum levels of triglycerides, apolipoprotein-B, gamma-glutamyl transferase, and alkaline phosphatase. Additionally, MLXIPL Gln241His carriers were associated with significantly higher serum levels of HDL cholesterol and alanine aminotransferase. Carriers homozygous for MLXIPL Gln241His showed a higher risk of SLD in 2 unrelated cohorts. Carriers of MLXIPL Gln241His were especially more likely to be diagnosed with SLD if they were female, obese, and/or also carried the PNPLA3 I148M variant. Furthermore, the heterozygous carriage of MLXIPL Gln241His was associated with significantly higher all-cause, liver-related, and cardiovascular mortality rates. Nuclear magnetic resonance metabolomics data indicated that carriage of MLXIPL Gln241His was significantly associated with lower serum levels of VLDL and increased serum levels of HDL cholesterol.</p>
CONCLUSIONS: Analyses of the MLXIPL Gln241His polymorphism showed a significant association with a higher risk of SLD diagnosis and elevated serum alanine aminotransferase as well as significantly lower serum triglycerides and apolipoprotein-B levels. MLXIPL might, therefore, be a potential pharmacological target for the treatment of SLD and hyperlipidemia, notably for patients at risk. More mechanistic studies are needed to better understand the role of MLXIPL Gln241His on lipid metabolism and steatosis development.</p>
14 Authors
- Leonida Hehl
- Kate T Creasy
- Cecilia Vitali
- Eleonora Scorletti
- Katharina S Seeling
- Mara S Vell
- Miriam D Rendel
- Donna Conlon
- Marijana Vujkovic
- Inuk Zandvakili
- Christian Trautwein
- Kai M Schneider
- Daniel J Rader
- Carolin V Schneider
1 Application
| Application ID | Title |
|---|---|
| 71300 | Elucidating host-environment interactions in gastrointestinal diseases |
Enabling scientific discoveries that improve human health